Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

References

• World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2012: estimated incidence, mortality and prevalence worldwide in 2012. Prostate cancer fact sheet. 2015. [cited 2017 May 2]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp
   Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652–1659.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642.
   PubMed Web of Science ®Google Scholar
• Lowrance WT, Roth BJ, Kirkby E, et al. Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol. 2016;195:1444–1452.
   PubMed Web of Science ®Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis. 2011;14:177–183.
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–583.
   PubMed Web of Science ®Google Scholar
• Graff JN, Beer TM. Reducing skeletal-related events in metastatic castration-resistant prostate cancer. Oncology (Williston Park). 2015;29:416–423.
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–1192.
   PubMed Web of Science ®Google Scholar
• Lloyd AJ, Kerr C, Penton J, et al. Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: a survey capturing experiences from a diverse sample of UK patients. Value Health. 2015;18:1152–1157.
   PubMed Web of Science ®Google Scholar
• McDougall JA, Bansal A, Goulart BH, et al. The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone. Oncologist. 2016;21:320–326.
   PubMed Web of Science ®Google Scholar
• McKay R, Haider B, Duh MS, et al. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases. Prostate Cancer Prostatic Dis. 2017. DOI:10.1038/pcan.2017.4. [Epub ahead of print].
   PubMedGoogle Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520.
   PubMed Web of Science ®Google Scholar
• Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.
   PubMed Web of Science ®Google Scholar
• McNeel DG, Bander NH, Beer TM, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016;4:92.
   PubMed Web of Science ®Google Scholar
• Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016;355:i4405.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–992.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–160.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
   PubMed Web of Science ®Google Scholar
• Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117–124.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099–1105.
   PubMed Web of Science ®Google Scholar
• Xofigo (radium Ra 223 dichloride) injection, for intravenous use [prescibing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2016.
   Google Scholar
• Bruland OS, Nilsson S, Fisher DR, et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s–6257s.
   PubMed Web of Science ®Google Scholar
• Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44:252–259.
   PubMed Web of Science ®Google Scholar
• Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–3125.
   PubMed Web of Science ®Google Scholar
• Suominen MI, Fagerlund KM, Rissanen JP, et al. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res. 2017. [Epub ahead of print]. DOI:10.1158/1078-0432.CCR-16-2955.
   PubMedGoogle Scholar
• Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1384–1393.
   PubMed Web of Science ®Google Scholar
• Chittenden SJ, Hindorf C, Parker CC, et al. A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56:1304–1309.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kaneta T, Takano S, et al. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases. Ann Nucl Med. 2016;30:453–460.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–4459.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–594.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–686.
   PubMed Web of Science ®Google Scholar
• Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189–197.
   PubMed Web of Science ®Google Scholar
• Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738–746.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Cislo P, Sartor O, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27:868–874.
   PubMed Web of Science ®Google Scholar
• Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–1406.
   PubMed Web of Science ®Google Scholar
• Parker C, Finkelstein SE, Michalski JM, et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70:875–883.
   PubMed Web of Science ®Google Scholar
• Parker C, Zhan L, Cislo P, et al. Effect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer. 2017;71:1–6.
   PubMed Web of Science ®Google Scholar
• Zimmerman BE, Bergeron DE, Cessna JT, et al. Revision of the NIST standard for 223Ra: new measurements and review of 2008 data. J Res Natl Inst Stand Technol. 2015;120:37–57.
   PubMed Web of Science ®Google Scholar
• Sartor O, Coleman RE, Nilsson S, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28:1090–1097.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Coleman RE, Michalski JM, et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer. 2017;15:42–52.e48.
   PubMed Web of Science ®Google Scholar
• Parker C, Vogelzang NJ, Sartor AO, et al. 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from ALSYMPCA. J Clin Oncol. 2015;33:abstr 195.
   PubMed Web of Science ®Google Scholar
• Sartor O, Hoskin P, Coleman RE, et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016;76:905–916.
   PubMed Web of Science ®Google Scholar
• Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17:1306–1316.
   PubMed Web of Science ®Google Scholar
• Sartor O, Fernandez D, Morris MJ, et al. Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting. J Clin Oncol. 2015;33(Suppl 7):abstr 253.
   Web of Science ®Google Scholar
• Sternberg CN, Procopio G, Seregni E, et al. Radium-223 alpha emitter agent in safety study in mCRPC popUlation for long-teRm evaluation (REASSURE). Ann Oncol. 2015;26(Suppl 6):vi64–vi64.
   Google Scholar
• Gkialas IK, Fragkoulis C. Emerging therapies targeting castration-resistant prostate cancer. J BUON. 2015;20:1389–1396.
   Google Scholar
• Morris MJ, Hammers HJ, Sweeney C, et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC). J Clin Oncol. 2013;31(Suppl):5021–5021.
   Google Scholar
• Smith M, Parker C, Tombal B, et al. ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer. J Clin Oncol. 2016;34(Suppl.):TPS5082.
   Google Scholar
• Petrylak DP, Rosenberg JA, Garosi VL, et al. A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases. J Clin Oncol. 2014;32(Suppl):TPS5103.
   Google Scholar
• Sartor O, Heinrich D, Mariados N, et al. Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases. Ann Oncol. 2016;27(Suppl. 6):752P–752P.
   PubMed Web of Science ®Google Scholar
• Sun Y, Shi H, Chen C et al. Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. Poster 243PD. Presented at: European Society for Medical Oncology; December 18-21, 2015; Singapore. http://oncologypro.esmo.org/Meeting-Resources. 2015.
   Google Scholar
• Coleman RE, Huang L, Petrenciuc O, et al. A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients (pts) with bone metastases (mets). J Clin Oncol. 2015;33(Suppl.):TPS1104.
   Google Scholar
• Rugo H, Petrenciuc O, Zhang A, et al. A phase 2 randomized double-blind placebo controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer. Ann Oncol. 2016;27:68–69.
   PubMed Web of Science ®Google Scholar
• Elaidi R, Vano YA, Aide N, et al. Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases. Ann Oncol. 2016;27(suppl 6):853 TiP.
   Google Scholar
• Bayer Inc. Canada. Product monograph: Xofigo. 2016. [cited 2017 May 2]. Available from: omr.bayer.ca/omr/online/xofigo-pm-en.pdf
   Google Scholar
• Bayer Pharma AG Xofigo: summary of product characteristics. 2016. [cited 2017 May 2]. Available from: www.ema.europa.eu/docs/en_GB/document…Product…/WC500156172.pdf
   Google Scholar
• Bayer Australia Ltd. XOFIGO solution for injection - product information. 2014. [cited 2017 May 2]. Available from: www.bayerresources.com.au/resources/uploads/PI/file10759.pdf
   Google Scholar
• Bayer New Zealand Limited. XOFIGO solution for injection - product monograph. 2014. [cited 2017 May 2]. Available from: www.bayerresources.com.au/resources/uploads/PM/file10774.pdf
   Google Scholar
• Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436–3448.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer—Version 2.2017. [cited 2017 May 2]. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Saad F, Chi KN, Finelli A, et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015;9:90–96.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (Technology appraisal guidance TA412). 2016. [cited 2017 May 2]. Available from: www.nice.org.uk.guidance/ta412
   Google Scholar
• Cancer Council Australia Advanced Prostate Cancer Guidelines Working Party. Management of locally advanced and metastatic prostate cancer. Sydney, Australia: Australian Cancer Network; 2010.
   Google Scholar
• Prostate Cancer Working Group and Ministry of Health. Prostate Cancer Management and Referral Guidance. Wellington, New Zealand: Ministry of Health; 2015.
   Google Scholar
• Singapore Cancer Network. Singapore Cancer Network (SCAN) guidelines for the management of advanced castrate-resistant prostate cancer. Ann Acad Med Singapore. 2015;44:397–405.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Fujimoto K. [The characteristics of Japanese clinical practice guideline for prostate cancer: A comparison with the guideline of Europe and the United States]. Nihon Rinsho. 2016;74(Suppl 3):256–261.
   PubMedGoogle Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746.
   PubMed Web of Science ®Google Scholar
• Steinberger AE, Cotogno P, Ledet EM, et al. Exceptional duration of radium-223 in prostate cancer with a BRCA2 mutation. Clin Genitourin Cancer. 2017;15:e69–e71.
   PubMedGoogle Scholar